247 related articles for article (PubMed ID: 33077513)
1. The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.
Boyiadzis MM; Aksentijevich I; Arber DA; Barrett J; Brentjens RJ; Brufsky J; Cortes J; De Lima M; Forman SJ; Fuchs EJ; Fukas LJ; Gore SD; Litzow MR; Miller JS; Pagel JM; Waller EK; Tallman MS
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077513
[TBL] [Abstract][Full Text] [Related]
2. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Luke JJ; Davar D; Andtbacka RH; Bhardwaj N; Brody JD; Chesney J; Coffin R; de Baere T; de Gruijl TD; Fury M; Goldmacher G; Harrington KJ; Kaufman H; Kelly CM; Khilnani AD; Liu K; Loi S; Long GV; Melero I; Middleton M; Neyns B; Pinato DJ; Sheth RA; Solomon SB; Szapary P; Marabelle A
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641350
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Material Technology for Leukemia Treatments.
Li F; Wang H; Ye T; Guo P; Lin X; Hu Y; Wei W; Wang S; Ma G
Adv Mater; 2024 Mar; ():e2313955. PubMed ID: 38547845
[TBL] [Abstract][Full Text] [Related]
4. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.
Zhang C; Wang XQ; Zhang RL; Liu F; Wang Y; Yan ZL; Song YP; Yang T; Li P; Wang Z; Ma YY; Gao L; Liu Y; Gao L; Kong PY; Liu J; Tan X; Zhong JF; Chen YQ; Liang AB; Ren JH; Li ZY; Cao J; Gao QL; Zhou J; Gao Y; Zhang D; Fan FY; Han MZ; Gale RP; Zhang X
Leukemia; 2021 Jun; 35(6):1563-1570. PubMed ID: 33077866
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R; Bassan R; Vitale A; Elia L; Piciocchi A; Puzzolo MC; Canichella M; Viero P; Ferrara F; Lunghi M; Fabbiano F; Bonifacio M; Fracchiolla N; Di Bartolomeo P; Mancino A; De Propris MS; Vignetti M; Guarini A; Rambaldi A; Chiaretti S;
N Engl J Med; 2020 Oct; 383(17):1613-1623. PubMed ID: 33085860
[TBL] [Abstract][Full Text] [Related]
6. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
Willier S; Rothämel P; Hastreiter M; Wilhelm J; Stenger D; Blaeschke F; Rohlfs M; Kaeuferle T; Schmid I; Albert MH; Binder V; Subklewe M; Klein C; Feuchtinger T
Blood; 2021 Feb; 137(8):1037-1049. PubMed ID: 33094319
[TBL] [Abstract][Full Text] [Related]
7. A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.
Wang Y; Yang Y; Hong R; Zhao H; Wei G; Wu W; Xu H; Cui J; Zhang Y; Chang AH; Hu Y; Huang H
Blood Cancer J; 2020 Oct; 10(10):105. PubMed ID: 33077713
[No Abstract] [Full Text] [Related]
8. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
9. Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.
Fernández de Larrea C; Staehr M; Lopez AV; Ng KY; Chen Y; Godfrey WD; Purdon TJ; Ponomarev V; Wendel HG; Brentjens RJ; Smith EL
Blood Cancer Discov; 2020 Sep; 1(2):146-154. PubMed ID: 33089218
[TBL] [Abstract][Full Text] [Related]
10. Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET.
Simonetta F; Alam IS; Lohmeyer JK; Sahaf B; Good Z; Chen W; Xiao Z; Hirai T; Scheller L; Engels P; Vermesh O; Robinson E; Haywood T; Sathirachinda A; Baker J; Malipatlolla MB; Schultz LM; Spiegel JY; Lee JT; Miklos DB; Mackall CL; Gambhir SS; Negrin RS
Clin Cancer Res; 2021 Feb; 27(4):1058-1068. PubMed ID: 33087332
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide.
Webster JA; Luznik L; Tsai HL; Imus PH; DeZern AE; Pratz KW; Levis MJ; Gojo I; Showel MM; Prince G; Bolaños-Meade J; Gondek LP; Ghiaur G; Dalton WB; Jain T; Fuchs EJ; Gladstone DE; Gocke CB; Ali SA; Huff CA; Borrello IM; Swinnen L; Wagner-Johnston N; Ambinder RF; Jones RJ; Smith BD
Blood Adv; 2020 Oct; 4(20):5078-5088. PubMed ID: 33080006
[TBL] [Abstract][Full Text] [Related]
12. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children.
Diorio C; Shaw PA; Pequignot E; Orlenko A; Chen F; Aplenc R; Barrett DM; Bassiri H; Behrens E; DiNofia AM; Gonzalez V; Koterba N; Levine BL; Maude SL; Meyer NJ; Moore JH; Paessler M; Porter DL; Bush JL; Siegel DL; Davis MM; Zhang D; June CH; Grupp SA; Melenhorst JJ; Lacey SF; Weiss SL; Teachey DT
Blood Adv; 2020 Oct; 4(20):5174-5183. PubMed ID: 33095872
[TBL] [Abstract][Full Text] [Related]
14. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
[TBL] [Abstract][Full Text] [Related]
15. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
Dees S; Ganesan R; Singh S; Grewal IS
Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
[TBL] [Abstract][Full Text] [Related]
16. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.
Hong S; Brazauskas R; Hebert KM; Ganguly S; Abdel-Azim H; Diaz MA; Beattie S; Ciurea SO; Szwajcer D; Badawy SM; Gratwohl AA; LeMaistre C; Aljurf MDSM; Olsson RF; Bhatt NS; Farhadfar N; Yared JA; Yoshimi A; Seo S; Gergis U; Beitinjaneh AM; Sharma A; Lazarus H; Law J; Ulrickson M; Hashem H; Schoemans H; Cerny J; Rizzieri D; Savani BN; Kamble RT; Shaw BE; Khera N; Wood WA; Hashmi S; Hahn T; Lee SJ; Rizzo JD; Majhail NS; Saber W
Cancer; 2021 Feb; 127(4):609-618. PubMed ID: 33085090
[TBL] [Abstract][Full Text] [Related]
17. The distinct MHC-unrestricted immunobiology of innate-like and adaptive-like human γδ T cell subsets-Nature's CAR-T cells.
Willcox CR; Mohammed F; Willcox BE
Immunol Rev; 2020 Nov; 298(1):25-46. PubMed ID: 33084045
[TBL] [Abstract][Full Text] [Related]
18. T-cell-engaging Therapy for Solid Tumors.
de Miguel M; Umana P; Gomes de Morais AL; Moreno V; Calvo E
Clin Cancer Res; 2021 Mar; 27(6):1595-1603. PubMed ID: 33082210
[TBL] [Abstract][Full Text] [Related]
19. CAR T-cell Characteristics Determine Efficacy.
Cancer Discov; 2020 Dec; 10(12):1780. PubMed ID: 33097479
[TBL] [Abstract][Full Text] [Related]
20. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia.
Ueno H; Yoshida K; Shiozawa Y; Nannya Y; Iijima-Yamashita Y; Kiyokawa N; Shiraishi Y; Chiba K; Tanaka H; Isobe T; Seki M; Kimura S; Makishima H; Nakagawa MM; Kakiuchi N; Kataoka K; Yoshizato T; Nishijima D; Deguchi T; Ohki K; Sato A; Takahashi H; Hashii Y; Tokimasa S; Hara J; Kosaka Y; Kato K; Inukai T; Takita J; Imamura T; Miyano S; Manabe A; Horibe K; Ogawa S; Sanada M
Blood Adv; 2020 Oct; 4(20):5165-5173. PubMed ID: 33095873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
